Marker Therapeutics is putting its future on MT-601. Now, the company has secured a manufacturing partner with the scale to match its plans. Kincellis Advanced Therapies, formed from the merger of Cellipont Bioservices and Kincell Bio, brings 140,000 square feet of US-based development and manufacturing space and 16 GMP suites across three sites. Marker says these resources are key as MT-601 heads toward pivotal trials and possible commercial launch.
Kincellis Advanced Therapies supports a wide range of advanced therapy programs, including autologous and allogeneic cell therapies such as CAR-T, Tregs, CAR-NK, MSCs, dendritic cell vaccines, exosomes, iPSCs, and synthetic mRNA.
Juan Vera, MD, President and CEO of Marker Therapeutics, is openly optimistic about the stronger partnership. He stresses how important expanded manufacturing is as MT-601 moves forward. MT-601 (neldaleucel) is Marker’s lead program. It is a multi-antigen T cell product that targets six tumor antigens found in lymphoma. The therapy is now in the Phase 1 APOLLO study (NCT05798897) for patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapies or cannot get those treatments.
Early results from the APOLLO trial are already getting attention. Among 12 patients with Non-Hodgkin Lymphoma, MT-601 showed a 66% objective response rate. Half of those patients reached complete remission. These early results set a high bar for the next phases and show why reliable, scalable manufacturing is urgent as Marker looks to later-stage development.
Kincellis Advanced Therapies was formed to expand late-stage and commercial manufacturing capacity, supporting programs from early-stage CMC and analytical/process development through clinical supply and pivotal-stage programs.
Marker Therapeutics, based in Houston, focuses on next-generation T cell therapies for blood cancers and solid tumors. The company’s move to double down on manufacturing at this stage is a calculated bet—one that could decide if MT-601 goes from a promising clinical candidate to a real commercial product. Manufacturing bottlenecks have stopped even the most promising cell therapies before. Marker’s early push to secure supply stands out as a rare case of planning ahead. If the APOLLO trial’s early momentum continues, this expanded partnership could be a turning point for Marker and for patients waiting for new options in relapsed lymphoma.
A Cell & Gene Therapy Review feature reports that Kincellis operates in Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas. This gives Marker a manufacturing network that is both geographically spread out and resilient.
